Ieq Capital LLC Invests $7.08 Million in Biohaven Ltd. $BHVN

Ieq Capital LLC purchased a new position in Biohaven Ltd. (NYSE:BHVN) during the second quarter, HoldingsChannel reports. The fund purchased 475,865 shares of the company’s stock, valued at approximately $7,081,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BHVN. AQR Capital Management LLC boosted its position in Biohaven by 49.4% during the first quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock worth $2,761,000 after purchasing an additional 37,981 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Biohaven by 32.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock worth $1,747,000 after buying an additional 17,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Biohaven by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock valued at $14,174,000 after acquiring an additional 41,040 shares during the last quarter. Intech Investment Management LLC increased its holdings in Biohaven by 80.3% during the 1st quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock valued at $1,481,000 after acquiring an additional 27,433 shares in the last quarter. Finally, Quantbot Technologies LP raised its position in Biohaven by 1,097.8% during the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock worth $125,000 after acquiring an additional 8,102 shares during the last quarter. 88.78% of the stock is owned by institutional investors and hedge funds.

Biohaven Price Performance

Biohaven stock opened at $13.91 on Monday. Biohaven Ltd. has a 12-month low of $7.48 and a 12-month high of $18.57. The stock has a market capitalization of $2.10 billion, a P/E ratio of -3.00 and a beta of 1.26. The firm’s 50-day moving average is $14.59 and its two-hundred day moving average is $11.74. The company has a debt-to-equity ratio of 21.23, a current ratio of 4.73 and a quick ratio of 4.73.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). Equities analysts predict that Biohaven Ltd. will post -3.29 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $10.00 price target on shares of Biohaven in a report on Tuesday, May 26th. Bank of America reissued an “underperform” rating and set a $11.00 price objective (down from $12.00) on shares of Biohaven in a research note on Monday, June 29th. Wall Street Zen upgraded Biohaven from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Royal Bank Of Canada upped their target price on Biohaven from $22.00 to $23.00 and gave the company an “outperform” rating in a research note on Tuesday, August 11th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Biohaven in a report on Friday, June 26th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $21.75.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.